4534.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 02:15):

Stats
Today's Volume	30 800.00
Average Volume	30 468.00
Market Cap	107.60B
EPS	¥0 ( 2024-05-13 )
Next earnings date	( ¥0 ) 2024-08-02
Last Dividend	¥40.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	23.96
ATR14	¥2.61 (0.09%)

Volume Correlation

Long: -0.13 (neutral)

Short: 0.68 (moderate)

Signal:(49.786) Neutral

Mochida Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mochida Pharmaceutical Correlation - Currency/Commodity

0.71
( moderate )

0.08
( neutral )

0.77
( moderate )

0.71
( moderate )

0.15
( neutral )

-0.71
( moderate negative )

Mochida Pharmaceutical Financials

Annual	2023
Revenue:	¥102.89B
Gross Profit:	¥52.07B (50.61 %)
EPS:	¥126.79

FY	2023
Revenue:	¥102.89B
Gross Profit:	¥52.07B (50.61 %)
EPS:	¥126.79

FY	2022
Revenue:	¥103.26B
Gross Profit:	¥55.12B (53.37 %)
EPS:	¥178.93

FY	2022
Revenue:	¥110.18B
Gross Profit:	¥59.55B (54.05 %)
EPS:	¥277.39

Financial Reports:

No articles found.

Mochida Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥40.00 (N/A)	¥0 (N/A)	¥40.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Mochida Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.29 - low (42.54%) | Divividend Growth Potential Score: 0.981 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥9.38	2001-03-27
Last Dividend	¥40.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥1 333.13	--
Avg. Dividend % Per Year	0.00%	--
Score	2.25	--
Div. Sustainability Score	4.29
Div.Growth Potential Score	0.981
Div. Directional Score	2.63	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

2.25

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6121.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
4828.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4041.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3249.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
2282.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
9142.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
7990.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7236.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6465.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
5602.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0442	1.500	9.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0286	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.0357	1.500	-0.715	-1.072	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.47	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.13	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.277	1.500	4.02	6.03	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2 901.00	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-6.29	2.00	-2.10	-4.19	[0 - 30]
freeCashFlowPerShareTTM	-30.54	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.506	1.000	4.90	4.90	[0.2 - 0.8]
operatingProfitMarginTTM	0.0564	1.000	-0.872	-0.872	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.648	0.800	9.01	7.21	[0.5 - 2]
Total Score				4.29

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	23.76	1.000	7.70	0	[1 - 100]
returnOnEquityTTM	0.0357	2.50	-0.460	-1.072	[0.1 - 1.5]
freeCashFlowPerShareTTM	-30.54	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	2.63	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-6.29	2.00	-2.10	-4.19	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	63.14	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00217	1.000	-2.55	0	[0.1 - 0.5]
Total Score				0.981

Mochida Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mochida Pharmaceutical

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.